Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles
Omicron 돌연변이는 SARS-CoV-2 바이러스 유사 입자의 감염성을 높이고 항체 중화를 감소시킵니다.
Article
Published on
Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,
Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
addition
Antibody neutralization
Antisera
assembly
B.1
B.1 lineage
B.1.1
bebtelovimab
Casirivimab
Cell
cell entry
change
convalescent sera
coronavirus
COVID-19
Delta
detectable
detrimental
dose
Effect
Efficacy
Efficiency
eight
eight subject
elicited
ENhance
examined
Imdevimab
individual
Johnson & Johnson
Johnson & Johnson
luciferase
Moderna
monoclonal antibodies
monoclonal antibody
Mutation
N proteins
neutralization
neutralization activity
neutralization titer
Neutralizing antibodies
neutralizing antibody
omicron
Omicron variant
Patient
Pfizer
Pfizer/BioNTech
Prevent
property
reduce
reduced
respiratory
resulting
robust
SARS-CoV-2
SARS-CoV-2 variant
sequence
sera
severe acute respiratory syndrome Coronavirus
Spike protein
Spread
structural protein
structural proteins
subjects
survivor
Vaccine
Vaccines
variant
variants
Viral
viral infectivity
Virus-like particle
virus-like particles
VLP
VLPs
[DOI] 10.1073/pnas.2200592119 PMC 바로가기 [Article Type] Article
[DOI] 10.1073/pnas.2200592119 PMC 바로가기 [Article Type] Article